Sage Therapeutic Stock Analysis

SAGE
 Stock
  

USD 42.94  0.96  2.29%   

The latest price surge of Sage Therapeutic created some momentum for shareholders as it was traded today as low as 42.3 and as high as 43.4 per share. The company management teams may have good odds in positioning the company resources to exploit market volatility in September. The stock standard deviation of daily returns for 90 days investing horizon is currently 3.62. The above-average risk is mostly attributed to market volatility and speculations regarding some of the upcoming earning calls from Sage Therapeutic Com partners.
Additionally, take a look at World Market Map.
  
The Sage Therapeutic stock analysis report makes it easy to digest most publicly released information about Sage Therapeutic and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Sage Therapeutic Stock analysis module also helps to analyze the Sage Therapeutic price relationship with some important fundamental indicators such as market cap and management efficiency.

Sage Therapeutic Stock Analysis Notes

About 13.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.37. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Sage Therapeutic Com recorded earning per share (EPS) of 11.06. The entity had not issued any dividends in recent years. Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Sage Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 471 people. To find out more about Sage Therapeutic Com contact Jeffrey Jonas at 617 299-8379 or learn more at www.sagerx.com.

Sage Therapeutic Com Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Sage Therapeutic's investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Sage Therapeutic Com or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Sage Therapeutic Com has very high historical volatility over the last 90 days
Sage Therapeutic Com is unlikely to experience financial distress in the next 2 years
The company reported the previous year's revenue of 6.31 M. Net Loss for the year was (484.18 M) with loss before overhead, payroll, taxes, and interest of (277.41 M).
Sage Therapeutic Com currently holds about 1.63 B in cash with (376.9 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 27.52.
Sage Therapeutic Com has a poor financial position based on the latest SEC disclosures
Over 87.0% of the company shares are owned by institutional investors
Latest headline from finance.yahoo.com: National Cancer Center Hospital in Tokyo Upgrades to MRIdian Linac for MRI-Guided Radiation Therapy and has treated its first patients - Yahoo Finance

Sage Therapeutic Com Upcoming and Recent Events

Earnings reports are used by Sage Therapeutic to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sage Therapeutic previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report23rd of February 2022
Next Financial Report3rd of May 2022
Next Fiscal Quarter End31st of December 2021
Next Fiscal Year End23rd of February 2022
Last Quarter Report30th of September 2021
Last Financial Announcement31st of December 2020

Sage Therapeutic Largest EPS Surprises

Earnings surprises can significantly impact Sage Therapeutic's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2014-11-11
2014-09-30-0.4-0.5-0.125 
2015-02-27
2014-12-31-0.43-0.57-0.1432 
2015-05-14
2015-03-31-0.49-0.66-0.1734 
View All Earnings Estimates

Sage Therapeutic Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 2.52 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Sage Therapeutic's market, we take the total number of its shares issued and multiply it by Sage Therapeutic's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Sage Therapeutic Profitablity

Sage Therapeutic's profitability indicators refer to fundamental financial ratios that showcase Sage Therapeutic's ability to generate income relative to its revenue or operating costs. If, let's say, Sage Therapeutic is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Sage Therapeutic's executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Sage Therapeutic's profitability requires more research than a typical breakdown of Sage Therapeutic's financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2022
Return on Investment(24.25) (26.16) 
Return on Average Assets(22.98) (24.80) 
Return on Average Equity(24.09) (26.00) 
Return on Invested Capital(2.09) (2.15) 

Management Efficiency

The entity has return on total asset (ROA) of (16.1) % which means that it has lost $16.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (26.74) %, meaning that it created substantial loss on money invested by shareholders. Sage Therapeutic management efficiency ratios could be used to measure how well sage therapeutic com manages its routine affairs as well as how well it operates its assets and liabilities. As of August 12, 2022, Return on Investment is expected to decline to -26.16. In addition to that, Return on Average Assets is expected to decline to -24.8. Sage Therapeutic Current Assets are projected to increase significantly based on the last few years of reporting. The past year's Current Assets were at 1.8 Billion. The current year Assets Non Current is expected to grow to about 1.9 M, whereas Net Current Assets as percentage of Total Assets are forecasted to decline to 85.16.
Last ReportedProjected for 2022
Book Value per Share 8.89  9.59 
Enterprise Value over EBIT(8.10) (8.74) 
Enterprise Value over EBITDA(8.94) (9.65) 
Price to Book Value 5.92  7.47 
Tangible Assets Book Value per Share 9.76  8.17 
Enterprise Value1.4 B1.3 B
Tangible Asset Value364.1 M392.8 M

Technical Drivers

As of the 12th of August 2022, Sage Therapeutic has the Coefficient Of Variation of 528.29, semi deviation of 2.89, and Risk Adjusted Performance of 0.2421. In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Sage Therapeutic Com, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to analyze and collect data for nineteen technical drivers for Sage Therapeutic Com, which can be compared to its competition. Please validate Sage Therapeutic Com treynor ratio, and the relationship between the variance and potential upside to decide if Sage Therapeutic is priced more or less accurately, providing market reflects its prevalent price of 42.94 per share. Given that Sage Therapeutic Com has jensen alpha of 0.6481, we advise you to double-check Sage Therapeutic Com's current market performance to make sure the company can sustain itself at a future point.

Sage Therapeutic Com Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Mid-point Price over period is an average of Sage Therapeutic Com highest and lowest prices attained during the given period.
.

Sage Therapeutic Com Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sage Therapeutic insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sage Therapeutic's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sage Therapeutic insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Benecchi Christopher over a month ago via Macroaxis 
Acquisition by Benecchi Christopher of 9500 shares of Sage Therapeutic subject to Rule 16b-3
Elizabeth Barrett over a month ago via Macroaxis 
Acquisition by Elizabeth Barrett of 9947 shares of Sage Therapeutic subject to Rule 16b-3
George Golumbeski over three months ago via Macroaxis 
Purchase by George Golumbeski of 8000 shares of Sage Therapeutic
Jeffrey Jonas over three months ago via Macroaxis 
Exercise or conversion by Jeffrey Jonas of 30944 shares of Sage Therapeutic subject to Rule 16b-3
Kimi Iguchi over three months ago via Macroaxis 
Exercise or conversion by Kimi Iguchi of 4500 shares of Sage Therapeutic subject to Rule 16b-3
Benecchi Christopher over three months ago via Macroaxis 
Acquisition by Benecchi Christopher of 11400 shares of Sage Therapeutic subject to Rule 16b-3
Steven Paul over six months ago via Macroaxis 
Sage Therapeutic exotic insider transaction detected
Benecchi Christopher over six months ago via Macroaxis 
Acquisition by Benecchi Christopher of 45000 shares of Sage Therapeutic subject to Rule 16b-3
Greene Barry E over a year ago via Macroaxis 
Purchase by Greene Barry E of 23640 shares of Sage Therapeutic
Albert Robichaud over a year ago via Macroaxis 
Payment of 1144 shares by Albert Robichaud of Sage Therapeutic subject to Rule 16b-3
Elizabeth Barrett over a year ago via Macroaxis 
Acquisition by Elizabeth Barrett of 10000 shares of Sage Therapeutic subject to Rule 16b-3
Kimi Iguchi over a year ago via Macroaxis 
Exercise or conversion by Kimi Iguchi of 948 shares of Sage Therapeutic subject to Rule 16b-3

Sage Therapeutic Predictive Daily Indicators

Sage Therapeutic intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Sage Therapeutic stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Sage Therapeutic Forecast Models

Sage Therapeutic time-series forecasting models is one of many Sage Therapeutic's stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sage Therapeutic's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Sage Therapeutic Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Sage Therapeutic stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Sage Therapeutic shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Sage Therapeutic. By using and applying Sage Therapeutic Stock analysis, traders can create a robust methodology for identifying Sage Therapeutic entry and exit points for their positions.
Last ReportedProjected for 2022
Operating Margin 48.16  47.88 
EBITDA Margin 48.39  48.11 
Gross Margin 91.23  103.09 
Profit Margin 48.96  48.67 
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. Sage Therapeutic operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 471 people.

Current Sage Therapeutic Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Sage Therapeutic analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Sage Therapeutic analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
73.16Hold19Odds
Sage Therapeutic Com current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Sage Therapeutic analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Sage Therapeutic stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Sage Therapeutic Com, talking to its executives and customers, or listening to Sage Therapeutic conference calls.
Sage Therapeutic Analyst Advice Details

Sage Therapeutic Stock Analysis Indicators

Sage Therapeutic Com stock analysis indicators help investors evaluate how Sage Therapeutic stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Sage Therapeutic shares will generate the highest return on investment. By understating and applying Sage Therapeutic stock analysis, traders can identify Sage Therapeutic position entry and exit signals to maximize returns.
Quick Ratio21.17
Fifty Two Week Low27.36
Revenue Growth-0.10%
Shares Short Prior Month3.12M
Average Daily Volume Last 10 Day605.67k
Average Daily Volume In Three Month802.64k
Shares Percent Shares Out6.03%
Short Percent Of Float8.00%
Forward Price Earnings-5.76
Float Shares51.59M
Fifty Two Week High47.75
Enterprise Value To Ebitda-0.87
Fifty Day Average35.13
Two Hundred Day Average36.97
Enterprise Value To Revenue67.25
Additionally, take a look at World Market Map. Note that the Sage Therapeutic Com information on this page should be used as a complementary analysis to other Sage Therapeutic's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Price Transformation module to use Price Transformation models to analyze depth of different equity instruments across global markets.

Complementary Tools for Sage Therapeutic Stock analysis

When running Sage Therapeutic Com price analysis, check to measure Sage Therapeutic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sage Therapeutic is operating at the current time. Most of Sage Therapeutic's value examination focuses on studying past and present price action to predict the probability of Sage Therapeutic's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Sage Therapeutic's price. Additionally, you may evaluate how the addition of Sage Therapeutic to your portfolios can decrease your overall portfolio volatility.
CEO Directory
Screen CEOs from public companies around the world
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Go
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
Go
Global Markets Map
Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Go
Is Sage Therapeutic's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sage Therapeutic. If investors know Sage Therapeutic will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sage Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
2.5 B
Quarterly Revenue Growth YOY
-0.086
Return On Assets
-0.18
Return On Equity
-0.29
The market value of Sage Therapeutic Com is measured differently than its book value, which is the value of Sage Therapeutic that is recorded on the company's balance sheet. Investors also form their own opinion of Sage Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Sage Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sage Therapeutic's market value can be influenced by many factors that don't directly affect Sage Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sage Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine Sage Therapeutic value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sage Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.